4d Molecular Therapeutics, INC. (FDMT) — SC 13G/A Filings
All SC 13G/A filings from 4d Molecular Therapeutics, INC.. Browse 17 SC 13G/A reports with AI-powered summaries and risk analysis.
SC 13G/A Filings (17)
- SC 13G/A Filing — Dec 6, 2024
- SC 13G/A Filing — Nov 15, 2024
- SC 13G/A Filing — Nov 14, 2024
- SC 13G/A Filing — Nov 14, 2024
- SC 13G/A Filing — Nov 14, 2024
- SC 13G/A Filing — Nov 14, 2024
- SC 13G/A Filing — Nov 13, 2024
- SC 13G/A Filing — Nov 12, 2024
- SC 13G/A Filing — Nov 8, 2024
- SC 13G/A Filing — Oct 21, 2024
- SC 13G/A Filing — Feb 14, 2024
- SC 13G/A Filing — Feb 14, 2024
- SC 13G/A Filing — Feb 14, 2024
- SC 13G/A Filing — Feb 14, 2024
- SC 13G/A Filing — Feb 13, 2024
-
BlackRock Amends 4D Molecular Therapeutics Stake to 7.0%
— Jan 25, 2024
BlackRock Inc. filed an amended SC 13G/A on January 25, 2024, disclosing its ownership in 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT). As of December 31, 202 -
Viking Global Amends 4DMT Stake, Signals Continued Interest
— Jan 8, 2024
Viking Global Investors LP, a major investment firm, filed an amended SC 13G/A on January 8, 2024, indicating a change in their beneficial ownership of 4D Molec
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX